Acquired Hemophilia A Treated with Recombinant Porcine Factor VIII: Case Report and Literature Review on Its Efficacy.

Bibliographic Details
Title: Acquired Hemophilia A Treated with Recombinant Porcine Factor VIII: Case Report and Literature Review on Its Efficacy.
Authors: Borro, Matteo1,2 borromatteo@libero.it, Tassara, Riccardo1,2, Paris, Luca1, Artom, Nathan1, Brignone, Marcello1, Rebella, Lara1, Tassara, Rodolfo1
Source: Hematology Reports. Mar2023, Vol. 15 Issue 1, p17-22. 6p.
Subject Terms: *BLOOD coagulation factor VIII, *HEMOPHILIA, *MYOCARDIAL infarction, *PARTIAL thromboplastin time
Abstract: Acquired hemophilia A (AHA) is a bleeding disorder due to the presence of neutralizing autoantibodies named inhibitors in patients with a previously normal hemostasis. Recent international recommendations suggest the use of bypassing agents or substitutive therapy as the first-line treatment, usually preferring the former. The adequate hemostatic therapy needs an accurate balance between bleeding and thrombotic risks. We report a clinical case of acquired hemophilia A successfully treated with recombinant porcine factor VIII (Susoctocog alfa) as the first-line treatment. Despite the patient having a high-risk thrombotic score and a history of recent myocardial infarction, our experience showed the absence of thrombotic complications related to the use of Susoctocog alfa and a complete restoration of hemostatic parameters. Limited literature is present on the use of recombinant porcine factor VIII as a first-line treatment, and our report supports its use, especially when the thrombotic risk is high. [ABSTRACT FROM AUTHOR]
Copyright of Hematology Reports is the property of MDPI and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Database: Academic Search Complete
More Details
ISSN:20388322
DOI:10.3390/hematolrep15010003
Published in:Hematology Reports
Language:English